Labcorp management check
LH · Health Care · Health Care Services · CEO Adam H. Schechter
Filings as of
Closest peers in Health Care Services
- 60CICigna80
- 126DVADaVita74
- 208ABBVAbbVie68
- 218DGXQuest Diagnostics67
- 223LHLabcorp66
- 305CVSCVS Health61
The seven checks
- GoodBeat its chosen peers
Have owners done well?
What $100 became since fiscal 2021
5255thDetail
$100 invested at the start of fiscal 2021 grew to $150, against $148 for the peer group the company picked itself.
- GoodPay rose and fell with returns
Does pay follow performance?
Pay actually paid $100 value, each on its own scale
9480thDetail
Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.88 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Watch2.1% of net income
What does the CEO cost owners?
$18.3m pay · $877.0m net income, FY2025
2328thDetail
$18.3m of reported pay in fiscal 2025, against $877.0m of net income.
- WatchCEO stake ≈ 1.8 years of pay
Do they own the stock?
102,565 shares ≈ $32.9m
6 mo: ▲ $0 bought · ▼ $4.8m sold
2826thDetail
The CEO holds 102,565 shares, directly or through trusts (unvested awards not counted): about 1.8 years of pay. 8 insiders sold $4.8m in the last six months and none bought. 6 of 12 sales ran on pre-arranged 10b5-1 plans.
- GoodShare count shrinking
Are owners being diluted?
Diluted shares −2.2% a year; flagged above +2%
Stock pay 0.9% of revenue
7770thDetail
Diluted shares changed -2.2% a year over the last three fiscal years. Stock-based pay was 0.9% of revenue in the latest year.
- Good7 leadership filings in 3 years
Is leadership stable?
7 filings under 8-K 5.02 in 3 years
CEO: Adam H. Schechter
9069thDetail
CEO in the pay table: Adam H. Schechter. 7 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- GoodNo red flags on file
Are the books clean?
Since 2021
- 0Restated
- 0Auditor changes
- 0Late filings
- 010-K amended
100100thDetail
No restatements, auditor changes or late filings since 2021.
Reading the scores
Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.
Hover a chart for its figures. Detail has the full reading.
Pay versus performance
From the proxy statement filed April 10, 2026.
Pay tied most to Adjusted operating income
Other key measuresAdjusted EPSAdjusted Operating IncomeRevenueRelative Total Shareholder Return
Show the figures
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | Adam H. Schechter | $18.3m | $30.1m | $4.2m | $150 | $148 | $877.0m |
| 2024 | — | $19.3m | $21.3m | $3.7m | $163 | $147 | $746.0m |
| 2023 | — | $16.0m | $23.8m | $4.1m | $160 | $143 | $418.0m |
| 2022 | — | $14.9m | −$2.3m | $4.4m | $140 | $140 | $1.3bn |
| 2021 | — | $20.6m | $49.7m | $4.7m | $186 | $143 | $2.4bn |
Insiders and the CEO's stakeSelling
- President & CEO
- Adam H Schechter
- Shares held
- 102,565
- At that filing's price
- ≈ $32.9m
- Latest Form 4
- Aug 11, 2026
8 insiders sold $4.8m in the last six months and none bought. 6 of 12 sales ran on pre-arranged 10b5-1 plans.
Open-market trades by officers and directors since May 21, 2026.
- SoldAdam H SchechterPresident & CEO · 10b5-1 plan$1.5mAug 11, 2026
- SoldKerrii B AndersonDirector · 10b5-1 plan$954kAug 17, 2026
- SoldBrian J CaveneyEVP, Pres of BLS, CMO & CSO$744kNov 10, 2026
- SoldPeter J WilkinsonSVP, Chief Accounting Officer$439kAug 3, 2026
Leadership and governance on file
All 15 filings
- Aug 14, 2026Leadership change8-K 5.02
- Feb 9, 2026Leadership change8-K 5.02
- Dec 15, 2025Leadership change8-K 5.02
- Dec 10, 2025Leadership change8-K 5.02
- Nov 24, 2025Leadership change8-K 5.02
- May 20, 2025Leadership change8-K 5.02
- Nov 19, 2024Leadership change8-K 5.02
- Sep 11, 2023Leadership change8-K 5.02
- Jun 7, 2023Leadership change8-K 5.02
- May 5, 2023Leadership change8-K/A 5.02
- May 5, 2023Leadership change8-K/A 5.02
- May 4, 2023Leadership change8-K 5.02
- May 4, 2023Leadership change8-K 5.02
- Jan 5, 2023Leadership change8-K 5.02
- Oct 13, 2022Leadership change8-K 5.02
Latest shareholder vote results: May 26, 2026, including the say-on-pay vote.
Where the money went
2021–2025: $5.4bn returned to owners in buybacks and dividends, 95% of net income, and $620.9m of pay in stock.
Show the figures
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $13.1bn | $11.9bn | $12.2bn | $13.0bn | $14.0bn |
| Net income | $2.4bn | $1.3bn | $418.0m | $746.0m | $877.0m |
| Stock-based pay | $132.9m | $116.8m | $128.7m | $116.7m | $125.8m |
| Buybacks | $1.7bn | $1.1bn | $1.0bn | $250.1m | $450.0m |
| Dividends | — | $195.2m | $254.0m | $243.1m | $240.7m |
| Diluted shares | 98m | 92m | 88m | 84m | 84m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.